Focus on production innovation, evolving regulations, and growing demand in animal feed and human nutrition to capture market opportunities in the choline chloride sector Choline Chloride Market ...
On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026Received ...
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...
"We believe that IV Choline Chloride has the potential to make a meaningful impact in this highly underserved population," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics, in ...
(RTTNews) - Protara Therapeutics, Inc. (TARA) has dosed the first patient in its pivotal Phase 3 registrational THRIVE-3 trial evaluating intravenous (IV) Choline Chloride in patients dependent on ...
(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment ...
A clinical-stage biotechnology company headquartered in New York, United States. The company runs clinical development through external trial sites in the United States and other regions, depending on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback